FDA Approves Treatment for Kaposi Sarcoma
The U.S. Food and Drug Administration (FDA) has approved pomalidomide (Pomalyst) for patients with AIDS-related Kaposi sarcoma whose disease has become resistant to highly active antiretroviral therapy (HAART), or in patients with Kaposi sarcoma who are HIV-negative.
Pomalidomide was previously granted accelerated approval, breakthrough therapy designation, and orphan drug designation.
“Patients with Kaposi sarcoma have had few options to manage their disease for two decades,” said Diane McDowell, MD, vice president, Hematology Global Medical Affairs, Bristol Myers Squibb in a press release. “We’re excited that the additional research into Pomalyst in this rare disease area has resulted in our ability to provide a much-needed oral treatment option for patients.”
Read the full press release here.